Applied DNA Sciences Files Proxy Statement
Ticker: BNBX · Form: DEF 14A · Filed: Aug 21, 2024 · CIK: 744452
| Field | Detail |
|---|---|
| Company | Applied Dna Sciences INC (BNBX) |
| Form Type | DEF 14A |
| Filed Date | Aug 21, 2024 |
| Risk Level | medium |
| Pages | 16 |
| Reading Time | 20 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
Related Tickers: APDN
TL;DR
APDN proxy statement filed, shareholders vote soon.
AI Summary
Applied DNA Sciences Inc. filed a definitive proxy statement (DEF 14A) on August 21, 2024, for its fiscal year ending September 30, 2024. The filing concerns the company's annual meeting and related corporate governance matters. The company is headquartered at 50 Health Sciences Drive, Stony Brook, NY.
Why It Matters
This filing provides shareholders with crucial information regarding voting matters, executive compensation, and board nominations ahead of the company's annual meeting.
Risk Assessment
Risk Level: medium — Proxy statements often contain information about executive compensation, board structure, and shareholder proposals that can impact a company's strategic direction and financial performance.
Key Numbers
- 20240930 — Fiscal Year End (The reporting period for this proxy statement.)
- 20240821 — Filing Date (The date the definitive proxy statement was filed with the SEC.)
Key Players & Entities
- APPLIED DNA SCIENCES INC (company) — Filer
- 50 HEALTH SCIENCES DRIVE (location) — Business Address
- STONY BROOK (location) — City
- NY (location) — State
- 11790 (location) — ZIP Code
- PROHEALTH MEDICAL TECHNOLOGIES INC (company) — Former Company Name
- DCC ACQUISITION CORP (company) — Former Company Name
- DATALINK CAPITAL CORP/TX/ (company) — Former Company Name
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide shareholders with information for the company's annual meeting, including details on voting matters, director nominations, and executive compensation.
When is the fiscal year end for Applied DNA Sciences, Inc. as stated in this filing?
The fiscal year end is September 30, 2024.
What is the company's main business address?
The company's business address is 50 Health Sciences Drive, Stony Brook, NY 11790.
Has Applied DNA Sciences, Inc. operated under previous names?
Yes, the company has previously operated under the names PROHEALTH MEDICAL TECHNOLOGIES INC, DCC ACQUISITION CORP, and DATALINK CAPITAL CORP/TX/.
What is the SEC file number for this filing?
The SEC file number is 001-36745.
Filing Stats: 4,886 words · 20 min read · ~16 pages · Grade level 12.8 · Accepted 2024-08-21 09:43:01
Key Financial Figures
- $0.001 — everse stock split of our common stock, $0.001 par value (" Common Stock "), at a rati
Filing Documents
- tm2420704-2_def14a.htm (DEF 14A) — 767KB
- bc_netloss-bw.jpg (GRAPHIC) — 51KB
- bc_revenues-bw.jpg (GRAPHIC) — 48KB
- bc_tsr-bw.jpg (GRAPHIC) — 49KB
- ic_chairper-bw.jpg (GRAPHIC) — 1KB
- ic_member-bw.jpg (GRAPHIC) — 1KB
- lg_applieddna-4c.jpg (GRAPHIC) — 11KB
- px_24appliedpxy01pg01-4c.jpg (GRAPHIC) — 281KB
- px_24appliedpxy01pg02-bw.jpg (GRAPHIC) — 251KB
- 0001104659-24-091485.txt ( ) — 1663KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 34
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 44 HOUSEHOLDING OF PROXY MATERIALS 46 OTHER BUSINESS 47 STOCKHOLDER PROPOSALS AND NOMINATIONS 48 ANNUAL REPORT ON FORM 10-K AND OTHER INFORMATION 49 APPENDIX A A-1 i TABLE OF CONTENTS APPLIED DNA SCIENCES, INC. 50 HEALTH SCIENCES DRIVE STONY BROOK, NEW YORK 11790 PROXY STATEMENT Our Board of Directors has made this Proxy Statement and related materials available to you on the Internet, or, upon your request, has delivered printed proxy materials to you by mail, in connection with the Board of Directors' solicitation of proxies for use at the 2024 Annual Meeting of Stockholders (the " Annual Meeting ") of Applied DNA Sciences, Inc. to be held online on Monday, September 30, 2024, beginning at 10:00 a.m., Eastern Time, and at any postponements or adjournments of the Annual Meeting. As a stockholder, you are invited to attend the Annual Meeting and are requested to vote on the items of business described in this Proxy Statement. Except as otherwise indicated, all share and per share information in this Proxy Statement gives effect to the reverse stock split of the Company's outstanding common stock at a ratio of one-for-twenty shares, which was approved by our Board of Directors on April 21, 2024 and was effected as of 12:01 a.m. Eastern Time on Thursday, April 25, 2024. ABOUT THE ANNUAL MEETING Why did I receive a notice in the mail regarding the Internet availability of proxy materials instead of a full set of proxy materials? In accordance with rules adopted by the Securities and Exchange Commission (" SEC "), we are providing access to our proxy materials over the Internet. Accordingly, we are sending a Notice Regarding Availability of Proxy Materials (the " Notice ") to our stockholders of record and beneficial owners as of the record date (for more information on the record date, see "— Who is entitled to vote at the Annual Me